Literature DB >> 15607718

Simultaneous determination of OSI-774 and its major metabolite OSI-420 in human plasma by using HPLC with UV detection.

Wenjiang Zhang1, Lillian L Siu, Malcolm J Moore, Eric X Chen.   

Abstract

A new method was developed and validated for quantitating OSI-774 and its metabolite OSI-420 in human plasma. Sample preparation involved initial extraction with methyl t-butyl ether followed by back extraction with HCl and re-extraction with methyl t-butyl ether. This extraction process resulted in significant improvement in the specificity, reproducibility and sensitivity. The analytes were separated on a Water Symmetry C18 analytical column and the mobile phase consisted of acetonitrile-0.05 M potassium phosphate buffer (42:58, v/v) (pH 4.8), and monitored at a wavelength 345 nm. Values of between- and within-day precision and accuracy for both OSI-774 and OSI-420 were <20%. This method was successfully applied to study steady-state pharmacokinetics of OSI-774 and OSI-420 in a phase II clinical trial.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15607718     DOI: 10.1016/j.jchromb.2004.10.016

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  10 in total

1.  ERBB3: Multifunctional enabler or primary actor in pancreatic cancer?

Authors:  Ralf Landgraf
Journal:  Cancer Biol Ther       Date:  2010-09-13       Impact factor: 4.742

Review 2.  Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets.

Authors:  Huixin Yu; Neeltje Steeghs; Cynthia M Nijenhuis; Jan H M Schellens; Jos H Beijnen; Alwin D R Huitema
Journal:  Clin Pharmacokinet       Date:  2014-04       Impact factor: 6.447

3.  Single-cell transcriptional changes associated with drug tolerance and response to combination therapies in cancer.

Authors:  Alexandre F Aissa; Abul B M M K Islam; Majd M Ariss; Cammille C Go; Alexandra E Rader; Ryan D Conrardy; Alexa M Gajda; Carlota Rubio-Perez; Klara Valyi-Nagy; Mary Pasquinelli; Lawrence E Feldman; Stefan J Green; Nuria Lopez-Bigas; Maxim V Frolov; Elizaveta V Benevolenskaya
Journal:  Nat Commun       Date:  2021-03-12       Impact factor: 14.919

Review 4.  Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines.

Authors:  Matthias Scheffler; Paola Di Gion; Oxana Doroshyenko; Jürgen Wolf; Uwe Fuhr
Journal:  Clin Pharmacokinet       Date:  2011-06       Impact factor: 6.447

5.  Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort.

Authors:  Miguel Quintela-Fandino; Christophe Le Tourneau; Ignacio Duran; Eric X Chen; Lisa Wang; Ming Tsao; Bizhan Bandarchi-Chamkhaleh; Nhu-Ann Pham; Trevor Do; Martha MacLean; Rakesh Nayyar; Michael W Tusche; Ur Metser; John J Wright; Tak W Mak; Lillian L Siu
Journal:  Mol Cancer Ther       Date:  2010-03-02       Impact factor: 6.261

6.  Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer.

Authors:  Masahide Fukudo; Yasuaki Ikemi; Yosuke Togashi; Katsuhiro Masago; Young Hak Kim; Tadashi Mio; Tomohiro Terada; Satoshi Teramukai; Michiaki Mishima; Ken-Ichi Inui; Toshiya Katsura
Journal:  Clin Pharmacokinet       Date:  2013-07       Impact factor: 6.447

7.  The concentration of erlotinib in the cerebrospinal fluid of patients with brain metastasis from non-small-cell lung cancer.

Authors:  Yanming Deng; Weineng Feng; Jing Wu; Zecheng Chen; Yicong Tang; Hua Zhang; Jianmiao Liang; Haibing Xian; Shunda Zhang
Journal:  Mol Clin Oncol       Date:  2013-09-23

8.  Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation.

Authors:  Yosuke Togashi; Katsuhiro Masago; Masahide Fukudo; Yasuhiro Tsuchido; Chiyuki Okuda; Young Hak Kim; Yasuaki Ikemi; Yuichi Sakamori; Tadashi Mio; Toshiya Katsura; Michiaki Mishima
Journal:  Cancer Chemother Pharmacol       Date:  2011-06-17       Impact factor: 3.333

9.  Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer.

Authors:  C A Townsley; P Major; L L Siu; J Dancey; E Chen; G R Pond; T Nicklee; J Ho; D Hedley; M Tsao; M J Moore; A M Oza
Journal:  Br J Cancer       Date:  2006-04-24       Impact factor: 7.640

10.  Good Clinical Response to Erlotinib in a Non-Small Cell Lung Cancer Patient Harboring Multiple Brain Metastases and a Double Active Somatic Epidermal Growth Factor Gene Mutation.

Authors:  Katsuhiro Masago; Yosuke Togashi; Masahide Fukudo; Tomohiro Terada; Kaoru Irisa; Yuichi Sakamori; Shiro Fujita; Young Hak Kim; Tadashi Mio; Ken-Ichi Inui; Michiaki Mishima
Journal:  Case Rep Oncol       Date:  2010-04-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.